Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01865786 · ClinicalTrials.gov registry record
A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP Indication
A clinical trial, sponsored by Gilead Sciences.
- Completed
- Registry status
- 99
- Enrollment target
NCT01865786 is a clinical trial that has completed, run by Gilead Sciences. The registered enrollment target is 99 participants.
The verdict
NCT01865786 has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- 99 participants
- Enrollment target
Study Summary
This is a prospective, observational study to describe pregnancy outcomes among HIV-1 uninfected pregnant women who are taking emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) (Truvada®) for a pre-exposure prophylaxis (PrEP) indication nested in the Antiretroviral Pregnancy Registry (APR). Information on subjects is provided to the APR prospectively (prior to the outcome of the pregnancy being known) through their healthcare provider, with follow-up obtained from the healthcare provider following determination of the pregnancy outcome.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2013-01-01 |
| Est. Completion | 2018-03-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01865786
The ClinicalTrials.gov registry entry for NCT01865786 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01865786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01865786 about?
NCT01865786 is a clinical study titled "A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP Indication". This is a prospective, observational study to describe pregnancy outcomes among HIV-1 uninfected pregnant women who are taking emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) (Truvada®) for a pre-exposure prophylaxis (PrEP) indication nested in the Antiretroviral Pregnancy Registry (APR). I...
What is the current status of trial NCT01865786?
This trial is currently completed. The enrollment target is 99 participants. The study started on 2013-01-01. Estimated completion is 2018-03-13.
Who is sponsoring clinical trial NCT01865786?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.